证券代码：603207 证券简称：小方制药 公告编号：2025-028 本次股票上市类型为首发股份；股票认购方式为网下，上市股 数为14,400,000股。 本次股票上市流通总数为14,400,000股。 本次股票上市流通日期为2025 年 8 月 26 日。 一、本次限售股上市类型 经中国证券监督管理委员会《关于同意上海小方制药股份有限公司首次公开 发行股票注册的批复》（证监许可[2023]2147号）同意注册，并经上海证券交易所 同意，上海小方制药股份有限公司（以下简称"公司"）首次公开发行人民币普 通股（A股）4,000万股，并于2024年8月26日在上海证券交易所主板上市交易。公 司首次公开发行股票完成后，总股本为16,000万股，其中有限售条件流通股 120,802,248股，占当时公司总股本的75.50%，无限售条件流通股39,197,752股， 占当时公司总股本的24.50%。 本 次 上 市 流 通 的 限 售 股 为 公 司 首 次 公 开 发 行 限 售 股 ， 股 份 数 量 为 14,400,000股，占公司总股本的比例约为8.97%。上述股份锁定期为自公司首次公 开发行股票并上市之日 ...

国信证券股份有限公司关于 上海小方制药股份有限公司 首次公开发行部分限售股上市流通事项的核查意见 国信证券股份有限公司（以下简称"国信证券"或"保荐机构"）作为上海 小方制药股份有限公司（以下简称"公司"或"小方制药"）首次公开发行股票 并上市的保荐机构，根据《证券发行上市保荐业务管理办法》等相关法律、法规 和规范性文件的要求，就小方制药首次公开发行部分限售股上市流通事项进行了 审慎尽职调查，核查情况如下： 一、本次限售股上市类型 经中国证券监督管理委员会《关于同意上海小方制药股份有限公司首次公 开发行股票注册的批复》（证监许可[2023]2147 号）同意注册，并经上海证券交 易所同意，上海小方制药股份有限公司（以下简称"公司"）首次公开发行人民 币普通股（A 股）4,000 万股，并于 2024 年 8 月 26 日在上海证券交易所主板上市 交易。公司首次公开发行股票完成后，总股本为 16,000 万股，其中有限售条件流通 股 120,802,248 股，占当时公司总股本的 75.50%，无限售条件流通股 39,197,752 股，占当时公司总股本的 24.50%。 本次上市 流通的限售股为 公司首次公开 ...

金融界消息 截至2025年8月19日收盘，小方制药（603207）报收于36.7元，下跌0.35%，换手率9.24%， 成交量3.70万手，成交金额1.36亿元。 通过天眼查大数据分析，上海小方制药股份有限公司共对外投资了2家企业，参与招投标项目2459次， 知识产权方面有商标信息28条，专利信息133条，此外企业还拥有行政许可484个。 来源：金融界 小方制药最新一期业绩显示，截至2025一季报，公司营业总收入1.29亿元、同比增长3.33%，归属净利 润5984.27万元，同比增长14.63%，扣非净利润5985.89万元，同比增长14.60%，流动比率7.598、速动比 率7.286、资产负债率9.76%。 天眼查商业履历信息显示，上海小方制药股份有限公司，成立于1993年，位于上海市，是一家以从事医 药制造业为主的企业。企业注册资本16055.9967万人民币，实缴资本12000万人民币。公司法定代表人 为FANG ZHIGUANG。 资金流向方面，今日主力资金净流出1449.96万元，占比成交额10.67%。其中，超大单净流入754.12万 元、占成交额5.55%，大单净流出2204.07万元、占成 ...

Core Viewpoint - The company, Xiao Fang Pharmaceutical, confirmed that its product, calamine lotion, has a certain inhibitory effect on itching caused by mosquito bites, and the market demand for this product remains stable [2] Group 1: Product Information - The calamine lotion product is effective in alleviating itching from mosquito bites [2] - The market demand for calamine lotion has been stable despite the outbreak of the Chikungunya virus in regions like Foshan and Guangzhou [2]

通过天眼查大数据分析，上海小方制药股份有限公司共对外投资了2家企业，参与招投标项目2455次， 知识产权方面有商标信息28条，专利信息133条，此外企业还拥有行政许可480个。 来源：金融界 小方制药最新一期业绩显示，截至2025一季报，公司营业总收入1.29亿元、同比增长3.33%，归属净利 润5984.27万元，同比增长14.63%，扣非净利润5985.89万元，同比增长14.60%，流动比率7.598、速动比 率7.286、资产负债率9.76%。 天眼查商业履历信息显示，上海小方制药股份有限公司，成立于1993年，位于上海市，是一家以从事医 药制造业为主的企业。企业注册资本16055.9967万人民币，实缴资本12000万人民币。公司法定代表人 为FANG ZHIGUANG。 金融界消息 截至2025年8月5日收盘，小方制药（603207）报收于37.52元，下跌2.65%，换手率 19.19%，成交量7.68万手，成交金额2.89亿元。 资金流向方面，今日主力资金净流出2611.68万元，占比成交额9.04%。其中，超大单净流出852.38万 元、占成交额2.95%，大单净流出1759.30万元、占成 ...

Core Viewpoint - Xiaofang Pharmaceutical (603207) experienced a significant increase of 6.23% in stock price, with a trading volume turnover rate of 31.10% and a total transaction value of 462 million yuan, indicating strong market interest and activity [2]. Trading Activity - The stock was listed on the Shanghai Stock Exchange due to its turnover rate reaching 31.10%, with institutional investors net buying 17.7364 million yuan [2]. - The top five trading departments accounted for a total transaction value of 110 million yuan, with a net buying amount of 3.9196 million yuan [2]. - Among the trading departments, one institutional special seat was noted as the top buyer, contributing a net purchase of 17.7364 million yuan [2]. Fund Flow - The stock saw a net inflow of 1.1686 million yuan in main funds, with large orders contributing a net inflow of 1.8799 million yuan, while large orders experienced a net outflow of 711,200 yuan [2]. - Over the past five days, the net inflow of main funds totaled 59.9802 million yuan [2]. Financial Performance - In the first quarter, Xiaofang Pharmaceutical reported a revenue of 129 million yuan, reflecting a year-on-year growth of 3.33%, and a net profit of 59.8427 million yuan, which is a year-on-year increase of 14.63% [2].

Group 1 - The stock of Xiaofang Pharmaceutical (603207) increased by 6.18% with a turnover rate of 30.15% and a trading volume of 439 million yuan, showing a fluctuation of 9.98% [2] - Institutional investors net bought 10.28 million yuan while the total net selling by brokerage seats amounted to 24.11 million yuan [2] - The stock was listed on the Shanghai Stock Exchange due to its turnover rate reaching 30.15%, with a significant net inflow of 38.57 million yuan from main funds [2] Group 2 - In the first quarter, Xiaofang Pharmaceutical reported a revenue of 129 million yuan, representing a year-on-year growth of 3.33%, and a net profit of 59.84 million yuan, which is a 14.63% increase compared to the previous year [2] - The top five brokerage seats accounted for a total transaction volume of 120 million yuan, with a buying amount of 52.90 million yuan and a selling amount of 66.72 million yuan, resulting in a net selling of 13.83 million yuan [2] - The main funds saw a net inflow of 54.88 million yuan over the past five days [2]

（原标题：小方制药7月30日龙虎榜数据） 小方制药(603207)今日上涨6.41%，全天换手率26.67%，成交额3.71亿元，振幅11.04%。龙虎榜数据显示，营业部席位合计净买入844.20万元。 上交所公开信息显示，当日该股因日换手率达26.67%上榜，营业部席位合计净买入844.20万元。 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交6323.76万元，其中，买入成交额为3583.98万元，卖出成交额为2739.78万元，合计 净买入844.20万元。 具体来看，今日上榜营业部中，第一大买入营业部为中信证券股份有限公司上海分公司，买入金额为928.24万元，第一大卖出营业部为国泰海通 证券股份有限公司总部，卖出金额为862.85万元。 资金流向方面，今日该股主力资金净流入2106.13万元，其中，特大单净流入741.15万元，大单资金净流入1364.98万元。近5日主力资金净流入 1177.06万元。 4月30日公司发布的一季报数据显示，一季度公司共实现营业收入1.29亿元，同比增长3.33%，实现净利润5984.27万元，同比增长14.63%。（数据 宝） 市盈率: 63.07倍 小方 ...

Core Viewpoint - The hair medical concept sector has shown a positive performance with a 1.77% increase, ranking 7th among various concept sectors, driven by significant gains in stocks like Xiaofang Pharmaceutical, Baicheng Pharmaceutical, and Jiuzhitang [1] Group 1: Sector Performance - The hair medical concept sector experienced a 1.77% increase, with 17 stocks rising, including Xiaofang Pharmaceutical (up 6.65%), Baicheng Pharmaceutical (up 6.05%), and Jiuzhitang (up 6.00%) [1] - The sector attracted a net inflow of 114 million yuan from main funds, with Jiuzhitang leading the inflow at 74.56 million yuan [1] Group 2: Fund Inflow Ratios - Baicheng Pharmaceutical, Aoyang Health, and Yisheng Pharmaceutical had the highest net inflow ratios at 10.73%, 7.21%, and 6.37% respectively [2] - Jiuzhitang recorded a net inflow of 74.56 million yuan with a turnover rate of 27.18% [2] - Other notable stocks include Langzi Co. (up 5.16% with a net inflow of 20.14 million yuan) and Aoyang Health (up 1.03% with a net inflow of 10.81 million yuan) [2]

Market Overview - On July 8, A-shares opened mixed, with the Shanghai Composite Index up by 0.04%, while the Shenzhen Component and ChiNext indices were in the red. However, by the time of reporting, all three indices turned positive, with the ChiNext index rising over 1% [1][2]. Sector Performance - The morning session saw gains in sectors such as electronics, building materials, telecommunications, and computers, with PCB, CRO, and consumer electronics outsourcing stocks performing well. Conversely, public utilities and banking sectors showed weakness [2][3]. PCB Sector - PCB concept stocks continued to strengthen, with International Composite Materials and Yidong Electronics hitting the 20% daily limit up. Jin'an Guoji achieved a four-day consecutive rise, while Honghe Technology had four limit-up days in six days [8][9]. Pharmaceutical Sector - The pharmaceutical sector was notably strong, with CRO, innovative drugs, and weight-loss drug stocks collectively rising. Lianhuan Pharmaceutical achieved a consecutive limit-up, while companies like Weixin Kang, Hasan Lian, and Xiaofang Pharmaceutical also hit the limit-up. Toxin Pharmaceutical and Ruizhi Pharmaceutical saw increases exceeding 10% [4][5][6]. Notable Stock Movements - Fujilai (301258) surged to a limit-up of 20.01%, reaching a price of 39.28 CNY per share shortly after opening. Other notable stocks included Tuoxin Pharmaceutical and Ruizhi Pharmaceutical, which rose by 13.27% and 12.88%, respectively [5][6]. Regulatory Issues - Ruiskanda faced a trading halt due to a 9.95% drop, attributed to regulatory issues involving its chairman and director, who are under criminal coercive measures for alleged violations related to information disclosure. The company had previously faced administrative penalties from the CSRC [11][13].